Market Overview

Geron Shares Rally Following Positive Results from Phase 2 Study of Imetelstat

Share:
Related GERN
Geron Mixed After Company Announces Start Of Phase 2/3 Clinical Trial
Piper Jaffray Sees Strength In Geron After News Of Drug Development

Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf.

Posted-In: News FDA Movers

 

Related Articles (GERN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters